NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.
Pollack SM, Jungbluth AA, Hoch BL, Farrar EA, Bleakley M, Schneider DJ, Loggers ET, Rodler E, Eary JF, Conrad EU 3rd, Jones RL, Yee C.
Pollack SM, et al. Among authors: jones rl.
Cancer. 2012 Sep 15;118(18):4564-70. doi: 10.1002/cncr.27446. Epub 2012 Feb 22.
Cancer. 2012.
PMID: 22359263
Free PMC article.